

CURRICULUM VITAE Eirini I. Rigopoulou

(last updated October 2019)

Associate Professor in Medicine/Consultant Physician/Hepatologist

Address (work): Faculty of Medicine, School of Health Sciences

University of Thessaly,
Panepistimiou str 3, Biopolis 41500
Larissa, Greece
Tel: +30 241350 2801
Fax: +30 241350 1557

Email: eirigopoulou@med.uth.gr, erigopoulou@yahoo.co.uk

ACADEMIC QUALIFICATIONS

December 1989	MD (Ptychion Iatrikes), Kapodistrian University of Athens, Greece (grade: very well).
November 1997	Specialty of Internal Medicine
June 2002	PhD, Kapodistrian University of Athens, Greece (grade: excellent)

PRESENT CLINICAL AND ACADEMIC APPOINTMENT

Feb 2016- today Associate Professor of Medicine, Consultant Physician/Hepatologist, Department of Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly

PAST CLINICAL ACADEMIC APPOINTMENTS

Oct 2007- Feb 2016 Assistant Professor of Medicine (tenure post from June 2011), Consultant Physician/Hepatologist, Department of Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Greece (Director: Professor G.N. Dalekos)

Feb 2003- Oct 2007 Lecturer in Medicine, Consultant Physician/Hepatologist, Department of Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Greece (Director: Professor N. Stathakis)

Mar 2001- Feb 2003 Consultant Physician/Hepatologist, Liver Unit, Athens Medical Center (Director: Prof. D. Tsantoulas)

Dec1998- Mar2001 Clinical Research Fellow, Institute of Hepatology, University College London Medical School, Supervisor: Professor N.V. Naoumov, Director: Professor R. Williams

Feb1999-Dec1999 Clinical Fellow, Liver Unit Cromwell Hospital (Director: Professor R. Williams)

Jan 1998- Nov 1998 Clinical Fellow, Liver and Liver Transplant Unit, Addenbrooke's Hospital, Cambridge, U.K (Director: Professor GJM Alexander)

Sep 1992-Sep1997 Specialty in Internal Medicine (Senior House Officer and Specialist Registrar), 1st Department of Internal Medicine, Sismanoglion Distirct Hospital, Athens, Greece (Director: Prof. D. Tsantoulas)
May1990- May 92 Community work at the District Medical Practice in Stavros, Ithaka, Greece

SCHOLARSHIPS/AWARDS

March 1997: Scholarship from the Hellenic Association for the Study of the Liver for postgraduate studies in Hepatology (Addenbrook's Hospital, University of Cambridge, UK)

September 1999-January 2001: Scholarship from Alexander S. Onassis Public Benefit Foundation to carry out research in Hepatology (Institute of Hepatology, UCL, UK)

September 2000: BASL Travel Bursary Award

Herakleitos General Secreteriat for Research & Technology (GSRT), Hellenic Ministry of Development: Support for the research of Dr M Bakarozzi

Herakleitos GSRT, Hellenic Ministry of Development: Support for the research of Dr A Koutsoumpas

Best research abstract award for the abstract entitled: "The diverse face of Familial Meditarrenean Fever (FMF) in Greece: The importance of R202Q mutation of Mediterranean fever (MEFV) gene" by the Foundation for the Development of Internal Medicine in Europe (FDIME) in the 18th European Congress of Internal Medicine, Lisbon, 29-31 August 2019

CLINICAL EXPERIENCE

General internal medicine

As a consultant physician since February 2003, when I joint the Department of Medicine of the University Hospital of Larissa, I was responsible in rotation (1:6 rota) with my consultant colleagues for the acute medical take assigned to the University Department of Medicine. The University Hospital of Larissa acts as a referral hospital for the whole region of Thessaly (Central Greece), with a population of around 1 million inhabitants.

Since I have become Assisant Professor and later on as Associate Professor, I had direct supervision of one chief resident (registrar), four senior house officers and 3 consultants with whom "post take" rounds were undertaken in general medical in-patients. These also function as post-graduate training sessions.

During my 5 years as a resident in internal medicine (SHO and Specialist Registrar post) in a district general hospital (Sismanoglion Hospital, Athens), I gained experience in all aspects of Internal Medicine and covered a 1:3 to 1:4 rota. I spent 8 months as a registrar in the ITU, where I received training in the care of medical and surgical patients with multi-organ failure requiring artificial ventilation, invasive haemodynamic monitoring and haemofiltration. I was one of the registrars covering the unit, which had 10 beds, and looked after patients following general surgical procedures, as well general surgical/medical ITU cases.

Hepatology

In my present appointment as Associate Professor of Medicine I am one of the 4 consultants, alongside with Professor G.N. Dalekos who are responsible for the care of patients with all aspects of acute or chronic liver diseases.

The Liver Unit is an intergrated servise within the Department of Medicine and provides in-patients and out-patients services. It acts as a referral center for the whole region of Thessaly. I have one general hepatology clinic per week. I have participated in numerous clinical trials.

In my training, I had the opportunity to gain experience in the management of all aspects of liver disease in in- and out-patients. During this period I participated in several clinical trials involving the management of patients with viral hepatitis.

As part of my training in Hepatology and Transplantation I spent one year at the Addenbrook's Hospital in Cambridge as a Clinical Fellow (Head: Professor G Alexander). I gained experience in the management of patients with acute and acute-on chronic-liver failure and in the management of complications post liver transplantation.

Subsequently, from November 1998 to Jauary 2001 as a Clinical Fellow at the Institute of Hepatology (University College London Medical School, Head: Professor NV Naoumov, Director: Professor Roger Williams) I participated in all aspects of clinical and educational activities, including radiology and histology sessions, audits, research in progress and journal clubs. I also participated in out-patients clinic and performed on weekly basis liver biopsies (Middlesex Hospital). From February 1999 to December 1999, I worked at the Liver Unit of Cromwell Hospital, where I was responsible for in-patients, who were under the care of Professor R. Williams. This work provided me with additional experience in advanced liver disease (acute liver failure, end strage liver disease, and hepatocellular carcinoma). Additionally, I participated in the living-related liver transplantation programm that was active during this period at Cromwell hospital.

UNDERGRADUATE AND POST-GRADUATE TEACHING EXPERIENCE AND MEDICAL EDUCATION

Undergraduate Teaching Responsibilities

I have been involved with undergraduate clinical training throughout my medical career. Since 2003, initially as a Lecturer, subsequently as Assistant Professor and now as Associate Professor of Medicine I was actively involved in teaching medical students in the clinical years (3rd, 4th, 6th year). I was assigned the tutorship for the teaching of "Internal Medicine" in 3rd year medical students during the academic year 2009-2010 and consecutively since academic year 2014-15. I am a regular examiner for 3rd, 4th and 6th year written and oral medical exams in Internal Medicine.

Postgraduate Teaching Responsibilities

I am involved in post-graduate teaching and training since 2003. This includes the supervision and teaching of registrars in clinical skills, as well as various aspects of clinical research. From 2008-2015, I co-coordinated the educational programm of the Department of Medicine of the University of Thessaly, which included case presentations, literature and research update on a weekly basis.

Since 2014 I have participated as examiner in the final written and oral examination for the accreditation of the speciality of Internal Medicine.

RESEARCH EXPERIENCE

- 1) Study of the immunopathogenesis of viral hepatitis B and C and of the immunomodulatory properties of agents such as ribavirin, IL-10, IL-12. This work was mainly conducted at the Institute of Hepatology, UCL, under the supervision of Professor N.V. Naoumov. Part of this work was presented as a PhD thesis in 2002 at the Kapodistrian University of Athens Medical School with the title: Study of parameters of immune responses in patients with chronic hepatitis C.
- 2) Study of the role of molecular mimicry in the induction of autoantibodies in autoimmune liver diseases and especially in patients with PBC. These projects were undertaken in collaboration with the group directed by Professor Diego Vergani, initially at the Institute of Hepatology, UCL and subsequently at the Institute of Liver Studies, King's College London.
- 3) Upon my return to my native country and following my academic appointment in the University of Thessaly Medical School, I continued my research on the study of viral hepatitis (epidemiology, pathogenesis, treatment) and autoimmune liver disease (oxidative stress, autoantibodies, immunopathogenesis). A number of these studies have been performed in collaboration with other Faculties of the University of Thessaly and renowned Clinical and Research Centers of Excellence in UK, Germany, Italy, and Spain (see analytical list of Collaborations).
- 4) Participation in numerous clinical trials related to chronic HBV, HCV and hepatocellular carcinoma and NASH.

London (October 2002): I also participated in a consensus meeting from 13 European countries in order to reach Europe-wide consensus guidelines for prevention of transmission of HBV and HCV from Health Care Workers to patients.

SUPERVISION OF PhD STUDENTS (February 2003- today)

1. First supervisor of 2 PhD students
2. Member of the tripartite supervisors committee of 13 PhD students
3. Internal examiner in 8 PhD viva examinations

GRANTS – FINANCIAL SUPPORT

1. **Hellenic Center for the Control of Infections (KEELPNO)** (1/1/2004-30/9/2004) - **8.804€** «Specialised services for the confirmation of HCV infection- an epidemiological survey»
2. **Alexander S. Onassis Public Benefit Foundation** (1/10/2006-30/9/2008) **24.200€** «Study of HBV specific immune responses in patients with occult HBV infection alone or in the presence of other liver diseases»
3. **E-rare consortium EPINOSTICS**. “Autoimmune liver diseases“. Epitope peptide mapping – The entry to novel and innovative diagnostic and therapeutic applications. (January 2008, duration 36 months). Project co-ordinator: Professor Hans-Jurgen Thiessen (Rostock Germany)
4. **Herakleitos General Secretariat for Research & Technology (GSRT), Hellenic Ministry of Development** 2010-2013 (Starting June 2011)- **45.000€**- Support for the research of Dr M Bakarozis
5. **Herakleitos GSRT, Hellenic Ministry of Development** 2010-2013 (Starting June 2011)- **45.000€**- Support for the research of Dr A Koutsoumpas).

6. **Innovation ticket (7.000€)**- Development of an enzyme linked immunoassay for the detection of IgG subclasses of autoantibodies. Funding body: (General Secretariat for Research and Education).

REVIEWER IN PEER REVIEW JOURNALS

Journal of Antimicrobial Chemotherapy

Autoimmunity

QJM

World J Hepatology

BMC Gastroenterology

Archives of Medical Science

Liver International

Annals of Gastroenterology

Biomed Research International

Expert Review of Gastroenterology and Hepatology

Clinical Developmental Immunology

Journal of Immunologic Research

Immuno-Gastroenterology

Transplantation Infectious Diseases

BMC Infectious Diseases

Expert Review Clinical Immunology

European Journal of Gastroenterology and Hepatology

Case Reports in Hepatology

Clinical Biochemistry

Member of the Editorial Board of Journal of Immunology Research
(<https://www.hindawi.com/journals/jir/editors/>)

Reviewer for grant giving bodies

Research Fund Secretariat, Food and Health Bureau, The Government of the Hong Kong Special Administrative region.

MEMBER OF SOCIETIES

1. Hellenic Association for the Study of the Liver
2. Society of Internal Medicine of North Greece
3. European Association for the Study of the Liver

ADMINISTRATIVE WORK

1. Member of the General Assembly of the Department of Medicine, University of Thessaly twice since 2003.
2. In September 2008, I was appointed as supervisor of 1 out of 3 medical teams of the Department of Internal Medicine, consisting of 1 chief resident (registrar), four senior house officers and 2 consultants with whom "post take" rounds are undertaken in general medical in-patients. These also function as post-graduate training sessions.
3. Deputy member of the Examination Committee based in Larissa, Thessaly up to 31/12/2011, which is responsible for the final written and oral examination for the accreditation of the speciality of Internal Medicine (Ministry of Health and Social Welfare- decision number Υ7α/Γ.Π. οικ. 70469, 12/6/2010).
4. Co-ordinator of the 'Support and Management of Chronic Alcohol Abusers' Out-patient

clinic of the University General Hospital of Larissa from 29/7/2010 (together with Assistant Professor of Psychiatry O. Mouzas) decision number (20/29/7/2010 (E.H.Δ.64°)).

5. Deputy member of the Examination Committee based in Larissa, Thessaly from 24/2/2014 up to 31/12/2015, which is responsible for the final written and oral examination for the accreditation of the speciality of Internal Medicine (Ministry of Health and Social Welfare- decision number Y7α/Γ.Π. οικ. 18286, 24/2/2014).
6. Member of the Examination Committee based in Larissa, Thessaly from 21 December 2017 up to the present, which is responsible for the final written and oral examination for the accreditation of the specialty of Internal Medicine.

MEMBER OF ORGANIZING COMMITTEES OF CONGRESSES/ CONFERENCES/SYMPOSIA

1. 1st Mediterranean Summer School, 21-24 September 1998
2. 5th Mediterranean Medical Congress, 25-27 September 1998
3. Postgraduate meeting in liver diseases, Athens, 23 March 2002
4. Internal Medicine Days Central Greece, 19-21 March 2009
5. Panhellenic Congress of Thalassaemias, 15-17 May 2009
6. Autumn days in Internal Medicine, Old Panteleimon, 25-26 September 2009
7. Participation in the scientific committee of 5th Educational congress of the Hellenic Foundation of Gastroenterology and Nutrition with the title: "Progress in Gastroenterology and Hepatology", Athens, 5-6 March 2010
8. 2nd Congress of Internal Medicine- Central Greece, 18-20 March 2010
9. Autumn days in Internal Medicine, Portalia Pilio, 1-2 October 2010
10. 3rd Congress of Internal Medicine- Central Greece, 10-12 March 2011
11. Scientific committee of the 6th International Congress of Internal Medicine of Central Greece, Larissa, 27-29 March 2014
12. Scientific committee of the 10th Educational congress of the Hellenic Foundation of Gastroenterology and Nutrition with the title: "Progress in Gastroenterology and Hepatology", Athens, 7-8 March 2015
13. Scientific committee of the 7th International Congress of Internal Medicine of Central Greece, Larissa 27-29 March 2015
14. Scientific committee of the 5th Panellenic Congress of Rheumatic and autoimmune diseases of central Greece, Larissa, 25-27 September 2015
15. Scientific committee of the 8th International Congress of Internal Medicine of Central Greece, Larissa 17-19 March 2016
16. Scientific committee of the 9th International Congress of Internal Medicine of Central Greece, Athens, 9-12 March 2017
17. Scientific committee of the 23rd Scientific congress of Hellenic medical students and of the 11th international forum of Hellenic medical students and young doctors, Larissa 12-14 May 2017
18. Scientific committee of the 10th International Congress of Internal Medicine of Greece, Athens, 22-24 March 2018

INVITATED SPEAKER

I have participated as Invited speaker in over 100 congresses or seminars.

PUBLICATIONS IN PEER REVIEW JOURNALS

List of Publications:

1. Shang D, Lin YH, **Rigopoulou I**, Chen B, Alexander GJ, Allain JP. Detection of TT virus DNA in patients with liver disease and recipients of liver transplant. **J Med Virol.** 2000; 61(4):455-61.
2. Evans PC, Smith S, Hirschfield G, **Rigopoulou E**, Wreghitt TG, Wight DG, Taylor CJ, Alexander GJ. Recipient HLA-DR3, tumour necrosis factor-alpha promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are interrelated risk factors for chronic rejection of liver grafts. **J Hepatol.** 2001; 34(5):711-5.
3. Lau GK, Suri D, Liang R, **Rigopoulou EI**, Thomas MG, Mullerova I, Nanji A, Yuen ST, Williams R, Naoumov NV. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. **Gastroenterology.** 2002; 122(3):614-24.
4. Gunson RN, Shouval D, Roggendorf M, Zaaijer H, Nicholas H, Holzmann H, de Schryver A, Reynders D, Connell J, Gerlich WH, Marinho RT, Tsantoulas D, **Rigopoulou E**, Rosenheim M, Valla D, Puro V, Struwe J, Tedder R, Aitken C, Alter M, Schalm SW, Carman WF; European Consensus Group. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. **J Clin Virol.** 2003; 27(3):213-30.
5. Bogdanos DP, Baum H, Grasso A, Okamoto M, Butler P, Ma Y, **Rigopoulou E**, Montalto P, Davies ET, Burroughs AK, Vergani D. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. **J Hepatol.** 2004; 40(1):31-9.
6. Bogdanos DP, Baum H, Butler P, **Rigopoulou EI**, Davies ET, Ma Y, Burroughs AK, Vergani D. Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. **Dig Liver Dis.** 2003; 35(11):801-5.
7. Bogdanos DP, Lenzi M, Okamoto M, **Rigopoulou EI**, Muratori P, Ma Y, Muratori L, Tsantoulas D, Mieli-Vergani G, Bianchi FB, Vergani D. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. **Int J Immunopathol Pharmacol.** 2004; 17(1):83-92 (original article).
8. Zachou K, **Rigopoulou E**, Liaskos C, Patsiaoura K, Makri E, Stathakis N, Dalekos GN. Primary biliary cirrhosis presented as peripheral eosinophilia in asymptomatic women with or without elevated alkaline phosphatase. **Eur J Gastroenterol Hepatol.** 2004; 16(4):425-8.
9. Abbott WG, **Rigopoulou E**, Haigh P, Cooksley H, Mullerova I, Novelli M, Winstanley A, Williams R, Naoumov NV. Single nucleotide polymorphisms in the interferon-gamma and interleukin-10 genes do not influence chronic hepatitis C severity or T-cell reactivity to hepatitis C virus. **Liver Int.** 2004; 24(2):90-7.
10. Bogdanos DP, Pares A, Baum H, Caballeria L, **Rigopoulou EI**, Ma Y, Burroughs AK, Rodes J, Vergani D. Disease-specific cross-reactivity between mimicking peptides of heat shock

protein of *Mycobacterium gordonae* and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. **J Autoimmun.** 2004; 22(4):353-62.

11. **Rigopoulou EI**, Dalekos GN. Anti-sp100 antibodies in primary biliary cirrhosis. **Scand J Gastroenterol.** 2004; 39(4):406-7.
12. Georgiadou SP, Zachou K, **Rigopoulou E**, Liaskos C, Mina P, Gerovasilis F, Makri E, Dalekos GN. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases. **J Viral Hepat.** 2004; 11(4):358-65.
13. Stefanidis I, Zervou EK, Rizos C, Syrganis C, Patsidis E, Kyriakopoulos G, Sdrakas L, Tsianas N, **Rigopoulou EI**, Liakopoulos V, Dalekos GN. Hepatitis E virus antibodies in hemodialysis patients: an epidemiological survey in central Greece. **Int J Artif Organs.** 2004; 27(10):842-7.
14. Zachou K, **Rigopoulou E**, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. **J Autoimmune Dis.** 2004; 1(1):2.
15. Tsirikoni A, Kyriakou DS, **Rigopoulou EI**, Alexandrakis MG, Zachou K, Passam F, Dalekos GN. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. **J Hepatol.** 2005; 42(3):393-9.
16. **Rigopoulou EI**, Davies ET, Pares A, Zachou K, Liaskos C, Bogdanos DP, Rodes J, Dalekos GN, Vergani D. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. **Gut.** 2005; 54(4):528-32.
17. Liaskos C, **Rigopoulou E**, Zachou K, Georgiadou S, Gatselis N, Papamihali R, Dalekos GN. Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. **J Autoimmun.** 2005; 24(3):251-60 (original article).
18. **Rigopoulou EI**, Abbott WG, Haigh P, Naoumov NV. Blocking of interleukin-10 receptor-- a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. **Clin Immunol.** 2005; 117(1):57-64 (original article).
19. **Rigopoulou EI**, Stefanidis I, Liaskos C, Zervou EK, Rizos C, Mina P, Zachou K, Syrganis C, Patsidis E, Kyriakopoulos G, Sdrakas L, Tsianas N, Dalekos GN. HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: results from five hemodialysis units in central Greece. **J Clin Virol.** 2005; 34(1):81-5.
20. Bogdanos DP, Baum H, Okamoto M, Montalto P, Sharma UC, **Rigopoulou EI**, Vlachogiannakos J, Ma Y, Burroughs AK, Vergani D. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its *Lactobacillus* mimic. **Hepatology.** 2005; 42(2):458-65.
21. Zachou K, **Rigopoulou EI**, Tsirikoni A, Alexandrakis MG, Passam F, Kyriakou DS, Stathakis NE, Dalekos GN. Autoimmune hepatitis type 1 and primary biliary cirrhosis

- have distinct bone marrow cytokine production. **J Autoimmun.** 2005; 25(4):283-8.
22. **Rigopoulou EI**, Suri D, Chokshi S, Mullerova I, Rice S, Tedder RS, Williams R, Naoumov NV. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. **Hepatology.** 2005; 42(5):1028-36.
 23. Stefanidis I, Liakopoulos V, **Rigopoulou EI**, Dalekos GN. Diagnostic discordance for hepatitis C virus infection in hemodialysis: correlations with clinical and laboratory features. **Am J Kidney Dis.** 2005; 46(5):992-3.
 24. Tzouvaras N, Stefanos A, Georgiadou SP, Gatselis N, Papadamou G, **Rigopoulou E**, Ioannou M, Skoularigis I, Dalekos GN. Reversion of severe hepatopulmonary syndrome in a non cirrhotic patient after corticosteroid treatment for granulomatous hepatitis: a case report and review of the literature. **World J Gastroenterol.** 2006; 12(2):336-9.
 25. Zachou K, Liaskos C, **Rigopoulou E**, Gabeta S, Papamichalis P, Gatselis N, Georgiadou S, Dalekos GN. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. **Clin Immunol.** 2006; 119(2):203-12.
 26. Zografos TA, **Rigopoulou EI**, Liaskos C, Togousidis E, Zachou K, Gatselis N, Germenis A, Dalekos GN. Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. **J Hepatol.** 2006; 44(5):848-55.
 27. **Rigopoulou EI**, Georgiadou SP, Barbanis S, Dalekos GN. Lack of association between appendectomy and primary biliary cirrhosis. **Scand J Gastroenterol.** 2006; 41(5):573-6.
 28. Bogdanos DP, Liaskos C, **Rigopoulou EI**, Dalekos GN. Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: revealing the unforeseen **Clin Chim Acta.** 2006; 373(1-2).
 29. Bogdanos DP, **Rigopoulou EI**. Self-mimicking autoimmune domains of hepatitis C virus core antigen. **Vaccine.** 2006; 24(37-39):6173-4
 30. Bogdanos DP, **Rigopoulou EI**. Viral/self-mimicry and immunological cross-reactivity as a trigger of hepatic C virus associated autoimmune diabetes. **Diabetes Res Clin Pract.** 2007; 77(1):155-6.
 31. Dalekos GN, Makaritsis K, **Rigopoulou EI**. Redesigning training for internal medicine. **Ann Intern Med.** 2006; 145(11):865.
 32. **E.I. Rigopoulou**, W. G.H. Abbott, R. Williams and N. V. Naoumov. Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. **Antiviral Research** 2007 Jul;75(1):36-42
 33. N.K. Gatselis, **E. Rigopoulou**, A. Stefanos, M. Kardasi and G.N. Dalekos. Risk factors associated with HCV infection in semi-rural areas of central Greece. **Eur J Intern Med** 2007; 18: 48-55.
 34. **E.I. Rigopoulou**, M. Mytilinaiou, O. Romanidou, C. Liaskos and G. N. Dalekos. Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. Journal: **Journal of Autoimmune Diseases**

2007 Feb 4;4:2.

35. **E.I. Rigopoulou**, D.P. Bogdanos, G. Dalekos. How common are connective tissue disorders in patients with autoimmune hepatitis? **Sem Arthritis Rheum** 2007 Apr;36(5):332.
36. C. Liaskos, D.P. Bogdanos, **E.I. Rigopoulou**, G.N. Dalekos. Development of anti-mitochondrial antibodies in patients with autoimmune hepatitis: an art of facts or an artifact? **J Gastroenterol Hepatol** 2007; 22(3):454-5.
37. N.K. Gatselis, A. Stefos, C. Gioti, **E.I. Rigopoulou** and G.N. Dalekos. Primary biliary cirrhosis and Henoch-Schonlein purpura: Report of two cases and review of the literature. **Liver International** 2007 Mar;27(2):280-3.
38. **E. I. Rigopoulou**, D-P. Bogdanos, C. Liaskos, A. Koutsoumpas, H. Baum, D. Vergani, G. N. Dalekos Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. **Clinica Chemica Acta** 2007; May 1;380(1-2):118-21.
39. Gabeta S, Norman GL, Liaskos C, Papamichalis PA, Zografos T, Garagounis A, **Rigopoulou EI**, Dalekos GN. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. **J Clin Immunol.** 2007 Jul;27(4):378-87.
40. Bogdanos DP, Liaskos C, Pares A, Norman G, **Rigopoulou EI**, Caballeria L, Dalekos GN, Rodes J, Vergani D. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. **Hepatology.** 2007 Jun;45(6):1583.
41. Papamichalis PA, Zachou K, Koukoulis GK, Veloni A, Karacosta EG, Kypri L, Mamaloudis I, Gabeta S, **Rigopoulou EI**, Lohse AW, Dalekos GN. The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. **J Autoimmune Dis.** 2007 Jun 29;4:3 (original article).
IF (2014):-
42. **Rigopoulou EI**, Davies ET, Bogdanos DP, Liaskos C, Mytilinaiou M, Koukoulis GK, Dalekos GN, Vergani D. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. **Liver Int.** 2007 Nov;27(9):1226-31.
43. Zografos TA, Liaskos C, **Rigopoulou EI**, Togousidis E, Makaritsis K, Germenis A, Dalekos GN. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. **Am J Gastroenterol.** 2008 Mar;103(3):605-14.
44. Tsirikoni A, **Rigopoulou EI**, Zachou K, Liaskos C, Kyriakou D, Dalekos GN. Bone marrow findings in patients with autoimmune liver diseases. **J Gastroenterol Hepatol.** 2008 Aug;23(8 Pt 2):e416-21.
45. **Rigopoulou EI**, Dalekos GN. Autoimmune hepatitis: of host and pathogen. **Hepatology.** 2008 Jun;47(6):2147-8.

46. Gabeta S, Norman GL, Gatselis N, Liaskos C, Papamichalis PA, Garagounis A, Zachou K, **Rigopoulou EI**, Dalekos GN. IgA Anti-b2GPI Antibodies in Patients with Autoimmune Liver Diseases. **J Clin Immunol**. 2008; 28(5):501-11.
47. **Rigopoulou EI** and Dalekos GN, Molecular diagnostics of primary biliary cirrhosis. *Expert Opinion on Medical Diagnostics* 2008; 2(6): 621-634.
48. Georgiadou SP, Zachou K, Liaskos C, Gabeta S, **Rigopoulou EI**, Dalekos GN. Occult hepatitis B virus infection in patients with autoimmune liver diseases. **Liver Int**. 2009;29(3):434-42.
49. Stefos A, Gatselis N, Zachou K, **Rigopoulou E**, Hadjichristodoulou C, Dalekos GN. Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. **Eur J Intern Med**. 2009;20(1):35-43.
50. Liaskos C, Norman GL, Moulas A, Garagounis A, Goulis I, **Rigopoulou EI**, Dalekos GN. Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis. **Clin Chim Acta**. 2010;411(5-6):411-5.
51. Mina P, Georgiadou SP, Rizos C, Dalekos GN, **Rigopoulou EI**. Prevalence of occult hepatitis B virus infection in haemodialysis patients from central Greece. **World J Gastroenterol**. 2010;16(2):225-31.
52. **Rigopoulou EI**, Dalekos GN. Can mathematical models be useful in clinical hepatology? **Liver Int**. 2010 May;30(5):637-8.
53. Gatselis NK, Zachou K, Papamichalis P, Koukoulis GK, Gabeta S, Dalekos GN, **Rigopoulou EI**. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score? **Dig Liver Dis**. 2010 Nov;42(11):807-12.
54. Zachou K, Gatselis N, Papadamou G, **Rigopoulou EI**, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. **J Hepatol**. 2011 Sep;55(3):636-46.
55. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H, Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP; HIDIT Study Group.
Collaborators: Akarca US, Berg T, Böcher W, Bohle H, Buggisch P, Cornberg M, Ersöz G, Feyerabend S, Hinrichsen H, Manok M, Häussinger D, Herzog W, Hofmann WP, Plein K, Hardt H, Porst H, Mederacke I, **Rigopoulou I**, Şentürk H, Tabak F, v Wagner EK, Yalçın K. Peginterferon plus adefovir versus either drug alone for hepatitis delta. **N Engl J Med**. 2011 Jan 27;364(4):322-31.
56. Smyk D, Mytilinaïou MG, **Rigopoulou EI**, Bogdanos DP. PBC triggers in water reservoirs, coal mining areas and waste disposal sites: from Newcastle to New York. **Dis Markers**. 2010;29(6):337-44.
57. Smyk D, **Rigopoulou EI**, Baum H, Burroughs AK, Vergani D, Bogdanos DP. Autoimmunity

and Environment: Am I at risk? **Clin Rev Allergy Immunol.** 2012; 42: 199-212

58. Koutsoumpas A, Polymeros D, Tsiamoulos Z, Smyk D, Karamanolis G, Triantafyllou K, **Rigopoulou EI**, Forbes A, Vergani D, Bogdanos DP, Ladas SD. Peculiar antibody reactivity to human connexin 37 and its microbial mimics in patients with Crohn's disease. **J Crohns Colitis.** 2011 Apr;5(2):101-9
59. Papamichalis P, Argyraki K, Papamichalis M, Loukopoulos A, Dalekos GN, **Rigopoulou EI**. Salmonella enteritidis Infection Complicated by Acute Myocarditis: A Case Report and Review of the Literature. **Cardiol Res Pract.** 2011;2011:574230.
60. Smyk D, Cholongitas E, Kriese S, **Rigopoulou EI**, Bogdanos DP. Primary biliary cirrhosis: family stories. **Autoimmune Dis.** 2011;2011:189585.
61. Smyk DS, Bogdanos DP, Kriese S, Billinis C, Burroughs AK, **Rigopoulou EI**. Urinary tract infection as a risk factor for autoimmune liver disease: From bench to bedside. **Clin Res Hepatol Gastroenterol.** 2012; 36:110-21
62. Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, **Rigopoulou EI**. Reactivation of resolved hepatitis B virus infection after immunosuppression: Is it time to adopt pre-emptive therapy? **Clin Res Hepatol Gastroenterol.** 2012; 36:84-93
63. Bogdanos DP, **Rigopoulou EI**, Smyk DS, Roggenbuck D, Reinhold D, Forbes A, Laass MW, Conrad K. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. **Autoimmun Rev.** 2011 Dec;11(2):143-8
64. Mavropoulos A, Smyk D, **Rigopoulou EI**, Bogdanos DP. Human peripheral blood mononuclear cell culture for flow cytometric analysis of phosphorylated mitogen-activated protein kinases. **Methods Mol Biol.** 2012;806:275-85 (original article)
IF (2014): 1.29
65. Smyk DS, **Rigopoulou EI**, Lleo A, Abeles RD, Mavropoulos A, Billinis C, Invernizzi P, Bogdanos DP. Immunopathogenesis of primary biliary cirrhosis: an old wives' tale. **Immun Ageing.** 2011 Dec 2;8(1):12
66. Smyk DS, **Rigopoulou EI**, Muratori L, Burroughs AK, Bogdanos DP. Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. **Ann Hepatol.** 2012 Jan-Feb;11(1):7-14
67. Bogdanos DP, Smyk DS, **Rigopoulou EI**, Mytilinaiou MG, Heneghan MA, Selmi C, Eric Gershwin M. Twin studies in autoimmune disease: Genetics, gender and environment. **J Autoimmun.** 2012; 38: J156-69
68. Rigamonti C, Bogdanos DP, Mytilinaiou MG, Smyk DS, **Rigopoulou EI**, Burroughs AK. Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. **Int J Rheumatol.** 2011;2011:976427.
69. Mytilinaiou MG, Meyer W, Scheper T, **Rigopoulou EI**, Probst C, Koutsoumpas AL, Abeles

- D, Burroughs AK, Komorowski L, Vergani D, Bogdanos DP. Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis. **Clin Chim Acta.** **2012**;413(15-16):1211-6.
70. **Rigopoulou EI**, Roggenbuck D, Smyk DS, Liaskos C, Mytilinaiou MG, Feist E, Conrad K, Bogdanos DP. Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found. **Autoimmun Rev.** **2012**;12:260-9.
 71. **Rigopoulou EI**, Smyk DS, Matthews CE, Billinis C, Burroughs AK, Lenzi M, Bogdanos DP. Epstein-barr virus as a trigger of autoimmune liver diseases. **Adv Virol.** **2012**;2012:987471.
 72. Smyk S, **Rigopoulou EI**, Pares A, Billinis C, Burroughs AK, Muratori L, Invernizzi P, Bogdanos DP. Sex differences associated with primary biliary cirrhosis **Clin Dev Immunol** **2012**; 2012;2012:610504.
 73. Smyk DS, **Rigopoulou EI**, Koutsoumpas AL, Kriese S, Burroughs AK, Bogdanos DP. Autoantibodies in autoimmune pancreatitis. **Int J Rheumatol.** **2012**;2012:940831.
 74. Smyk D, **Rigopoulou EI**, Zen Y, Billinis C, Pares A, Bogdanos DP. Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis? **World J Gastroenterol** **2012**; 18(35): 4855-4865
 75. Pavlidis P, Romanidou O, Roggenbuck D, Mytilinaiou MG, Al-Sulttan F, Liaskos C, Smyk DS, Koutsoumpas AL, **Rigopoulou EI**, Conrad K, Forbes A, Bogdanos DP. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease. **Clin Dev Immunol.** **2012**;2012:640835.
 76. Mavropoulos A, Orfanidou T, Liaskos C, Smyk DS, Billinis C, Blank M, **Rigopoulou EI**, Bogdanos DP. p38 mitogen-activated protein kinase (p38 MAPK)-mediated autoimmunity: lessons to learn from ANCA vasculitis and pemphigus vulgaris. **Autoimmun Rev.** **2013** Mar;12(5):580-90
 77. Bogdanos DP, Smyk DS, Invernizzi P, **Rigopoulou EI**, Blank M, Pouria S, Shoenfeld Y. Infectome: a platform to trace infectious triggers of autoimmunity. **Autoimmun Rev.** **2013**;12:726-40.
 78. Bogdanos DP, Smyk DS, Invernizzi P, **Rigopoulou EI**, Blank M, Sakkas L, Pouria S, Shoenfeld Y. Tracing environmental markers of autoimmunity: introducing the infectome. **Immunol Res.** **2013**;56:220-40.
 79. Liaskos C, Spyrou V, Roggenbuck D, Athanasiou LV, Orfanidou T, Mavropoulos A, Reinhold D, **Rigopoulou EI**, Amiridis GS, Billinis C, Bogdanos DP. Crohn's disease-specific pancreatic autoantibodies are specifically present in ruminants with paratuberculosis: implications for the pathogenesis of the human disease. **Autoimmunity.** **2013**;46:388-94.
 80. Liaskos C, **Rigopoulou EI**, Orfanidou T, Bogdanos DP, Papandreou CN. CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases. **Clin Dev Immunol.** **2013**;2013:968041.

- 81#. Mavropoulos A, Orfanidou T, Liaskos C, Smyk DS, Spyrou V, Sakkas LI, **Rigopoulou EI**, Bogdanos DP. p38 MAPK Signaling in Pemphigus: Implications for Skin Autoimmunity. *Autoimmune Dis.* 2013;2013:728529.
82. Mavropoulos A, **Rigopoulou EI**, Liaskos C, Bogdanos DP, Sakkas LI. The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis. *Clin Dev Immunol.* 2013;2013:569751.
83. **Rigopoulou EI**, Zachou K, Gatselis NK, Papadamou G, Koukoulis GK, Dalekos GN. Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. *World J Hepatol.* 2013;5:577-83.
84. Kabaçam G, Wedemeyer H, Savaş B, Keskin O, Dalekos G, Tabak F, Idilman R, Erhardt A, Yalçın K, Bozdayi MA, Bozkaya H, Manns M, Dienes H, Yurdaydın C; HIDIT-1 Study Group. Collaborators: Berg T, Böcher W, Bohle H, Buggisch P, Cornberg M, Ersöz G, Feyerabend S, Hinrichsen H, Manok M, Häussinger D, Herzog W, Hofmann WP, Plein K, Hardt H, Porst H, Mederacke I, **Rigopoulou EI**, Sentürk H, v Wagner E. Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. *Liver Int.* 2014;34:1207-15.
85. **Rigopoulou EI**, Zachou K, Gatselis N, Koukoulis GK, Dalekos GN. Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome. *Ann Hepatol.* 2013 Jan-2014 Feb;13:127-35.
86. **Rigopoulou EI**, Bogdanos DP. Is primary biliary cirrhosis rare or common? The truth lies somewhere in between. *Liver Int.* 2014;34:e165-7.
87. Smyk DS, Koutsoumpas AL, Mytilinaïou MG, **Rigopoulou EI**, Sakkas LI, Bogdanos DP. Helicobacter pylori and autoimmune disease: cause Or bystander. *World J Gastroenterol.* 2014;20(3):613-29.
88. Mavropoulos A, Bogdanos DP, Liaskos C, Orfanidou T, Simopoulou T, Zafiriou E, Sakkas LI, **Rigopoulou EI**. Flow cytometric detection of p38 MAPK phosphorylation and intracellular cytokine expression in peripheral blood subpopulations from patients with autoimmune rheumatic diseases. *J Immunol Res.* 2014;2014:671431.
89. Kaffe ET, **Rigopoulou EI**, Koukoulis GK, Dalekos GN, Moulas AN. Oxidative stress and antioxidant status in patients with autoimmune liver diseases. *Redox Rep.* 2015;20:33-41.
90. Raszeja-Wyszomirska J, Wunsch E, Krawczyk M, **Rigopoulou EI**, Bogdanos D, Milkiewicz P. Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis. *Liver Int.* 2015; 35:1764-71
91. Liaskos C, Spyrou V, Athanasiou LV, Orfanidou T, Mavropoulos , **Rigopoulou EI**, Amiridis GS, Shoenfeld Y, Billinis C, Bogdanos DP. Crohn's disease-specific anti-CU2D1 pancreatic antibodies are absent in ruminants with paratuberculosis. *Clin Res Hepatol Gastroenterol.* 2015;39(3):384-90.
92. Bogdanos DP, Smyk DS, **Rigopoulou EI**, Sakkas LI, Shoenfeld Y. Infectomics and

- autoinfectomics: a tool to study infectious-induced autoimmunity. **Lupus**. 2015; 24(4-5):364-73.
93. Raszeja-Wyszomirska J, Wunsch E, Krawczyk M, **Rigopoulou EI**, Kostrzewa K, Norman GL, Bogdanos DP, Milkiewicz P. Assessment of health related quality of life in polish patients with primary biliary cirrhosis. *Clin Res Hepatol Gastroenterol*. 2016 Sep;40(4):471-9.
 94. Zachou K, Gatselis NK, Arvaniti P, Gabeta S, **Rigopoulou EI**, Koukoulis GK, Dalekos GN. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. *Aliment Pharmacol Ther*. 2016 May;43(10):1035-47.
 95. Zachou K, Arvaniti P, Gatselis NK, Azariadis K, Papadamou G, **Rigopoulou E**, Dalekos GN. Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016? *Mediterr J Hematol Infect Dis*. 2017 Jan 1;9(1):e2017003.
 96. Wasik U, Wunsch E, Norman GL, **Rigopoulou EI**, Bogdanos DP, Milkiewicz P, Milkiewicz M. Polymorphisms of IL12RB2 May Affect the Natural History of Primary Biliary Cholangitis: A Single Centre Study. *Immunol Res*. 2017;2017:2185083.
 97. **Rigopoulou EI**, Ioannou M, Papadamou G, Dalekos GN. Ascites in a patient with episodic angio-oedema and eosinophilia: thinking outside the box. *BMJ Case Rep*. 2017 Apr 21;2017.
 98. Gatselis NK, Zachou K, Lygoura V, Azariadis K, Arvaniti P, Spyrou E, Papadamou G, Koukoulis GK, Dalekos GN, **Rigopoulou EI**. Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. *Eur J Intern Med*. 2017 Jul;42:81-88.
 99. Efthymiou G, Dardiotis E, Liaskos C, Marou E, Tsimourtou V, **Rigopoulou EI**, Scheper T, Daponte A, Meyer W, Sakkas LI, Hadjigeorgiou G, Bogdanos DP. Immune responses against *Helicobacter pylori*-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis. *Sci Rep*. 2017 Aug 11;7(1):7929.
 100. Papatheodoridis GV, **Rigopoulou EI**, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. *Antivir Ther*. 2018;23(8):677-685.
 101. Sveroni D, Stefos A, **Rigopoulou EI**, Dalekos GN. Rifampicin: not always an innocent drug. *BMJ Case Rep*. 2018 Dec 9;11(1).
 102. **Rigopoulou EI**, Gyftaki S, Arvaniti P, Tsimourtou V, Koukoulis GK, Hadjigeorgiou G, Dalekos GN. Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment. *Clin Res Hepatol Gastroenterol*. 2018 Dec 26. pii: S2210-7401(18)30273-0.
 103. Bakarozi M, Mavropoulos A, Bogdanos DP, Dalekos GN, **Rigopoulou EI**. p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B. *J Viral Hepat*. 2019 Sep 13. doi:

10.1111/jvh.13209. [Epub ahead of print]

104. Papatheodoridi M, Hadziyannis E, Berby F, Zachou K, Testoni B, **Rigopoulou E**, Gatselis NK, Lyberopoulou A, Vlachogiannakos I, Manolakopoulos S, Dalekos GN, Zoulim F, Papatheodoridis GV. Predictors of HBsAg loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in non-cirrhotic HBeAg-negative chronic hepatitis B. *J Viral Hepat.* 2019 Sep 28. doi: 10.1111/jvh.13211. [Epub ahead of print]

Chapters in books:

1. Dimitrios.P. Bogdanos, Cristina Rigamonti, Daniel Smyk, Maria G. Mytilinaiou, **Eirini I. Rigopoulou** and Andrew K. Burroughs. Emerging issues in the Immunopathogenesis, Diagnosis, and Clinical Management of Primary Biliary Cirrhosis associated Systemic Sclerosis. In: *Systemic Sclerosis- An update on the aberrant immune system and clinical features.* Timothy Radstake (Eds.) *Intech*; page 151-166.
2. **EI Rigopoulou**, D. Smyk, T. Orfanidou, DP.Bogdanos, ME. Gershwin. Bacterial infection in Liver. In: *Liver Immunology: Principles and Practice.* ME Gershwin, LM Vierling and MP Manns (Eds.), Springer; page 123-144.
3. DS. Smyk, **EI. Rigopoulou**, P. Invernizzi, DP. Bogdanos. Infection and Autoimmune Liver Diseases. In: *Infections and Autoimmunity.* Y. Shoenfeld, N. Agmon-Levin, NR Rose (Eds.) Elsevier; 2015, page 839-858

CITATIONS

Citations up to 23/10/2019 (source: Scopus)

Total number of citations (scopus): 3052

h-index (Scopus)=32